Based on the adverse effects of low HO-1 expression in immune cells, it has become possible to use HO-1 inducers to delay the progression of LN and even ameliorate the systemic conditions of SLE patients (Figure 4). Here, HMOX1 is linked to systemic lupus erythematosus.